0001209191-24-004438.txt : 20240305 0001209191-24-004438.hdr.sgml : 20240305 20240305181005 ACCESSION NUMBER: 0001209191-24-004438 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240229 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RENSCHLER MARKUS MD CENTRAL INDEX KEY: 0001217598 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40499 FILM NUMBER: 24723006 MAIL ADDRESS: STREET 1: C/O PHARMACYCLICS INC STREET 2: 995 E ARQUES AVE CITY: SUNNYVALE STATE: CA ZIP: 94085-4521 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cyteir Therapeutics, Inc. CENTRAL INDEX KEY: 0001662244 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 455429901 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HAYDEN AVENUE STREET 2: BUILDING B, SUITE 450 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 857-285-4140 MAIL ADDRESS: STREET 1: 99 HAYDEN AVENUE STREET 2: BUILDING B, SUITE 450 CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-02-29 0 0001662244 Cyteir Therapeutics, Inc. CYT 0001217598 RENSCHLER MARKUS MD C/O CYTEIR THERAPEUTICS, INC. 99 HAYDEN AVE, BUILDING B, SUITE 450 LEXINGTON MA 02421 1 1 0 0 President and CEO 0 Common Stock 2024-02-29 4 M 0 12607 1.69 A 1094820 D Common Stock 2024-02-29 4 M 0 2537 1.20 A 1097357 D Common Stock 2024-03-04 4 M 0 6304 1.69 A 1103661 D Stock Option (Right to Buy) 1.69 2024-02-29 4 M 0 12607 0.00 D 2033-02-03 Common Stock 12607 226952 D Stock Option (Right to Buy) 1.20 2024-02-29 4 M 0 2537 0.00 D 2024-02-01 2030-02-24 Common Stock 2537 0 D Stock Option (Right to Buy) 1.69 2024-03-04 4 M 0 6304 0.00 D 2033-02-03 Common Stock 6304 220648 D The option vests as to 1/48th of the underlying shares on each monthly anniversary of the vesting commencement date until the option is fully vested, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. /s/ David Gaiero, as attorney-in-fact for Markus Renschler, M.D. 2024-03-05